Frazier Healthcare Partners — 2025 Investments
5 investments dated 2025 · listed companies and verified rows first · show all
Alesta Therapeutics develops therapies for rare diseases, with research focused on genetic diseases and oncology.
BiotechHealthtech
Ilan Ganot(CEO)inBenit Maru(CMO)Matthias Van Woensel(CSO)in
Co-investorsDroia VenturesFrazier Life SciencesNovartis Venture FundRV Invest GmbHMPM BioImpactRTW Investments L.P.+1 more
Hillstar Bio develops precision immunotherapies for autoimmune diseases, using antibody engineering to selectively deplete pathogenic immune cells while sparing healthy ones.
BiotechHealthtech
Co-investorsDroia VenturesFrazier Life SciencesLifeArc Ventures
Iolyx is a pharmaceutical company focused on developing treatments for ocular conditions.
BiotechMedical Devices
Elizabeth Jeffords(CEO & President)inErin Newman(Chief Development Officer)inShannon Dahl(Chief Scientific Officer)inBryan Boyle(Chief Legal & Administrative Officer)in
Co-investorsAlumni VenturesFrazier Life Sciences
Tubulis develops antibody-drug conjugates (ADCs) for cancer treatment, using proprietary conjugation platform technologies to create tumor-targeting therapeutics.
BiotechDeep TechMedical DevicesPlanegg-Martinsried, DE
Dominik Schumacher(Co-founder & CEO)inJonas Helma-Smets(Co-founder & Chief Scientific Officer)Christian Hackenberger(Scientific Co-founder)
Co-investorsAndera PartnersBioMedPartnersEQT Life SciencesNexTech VenturesAscenta CapitalBayern Kapital+7 more
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Callio Therapeutics
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.


















